| Literature DB >> 16370382 |
Abstract
Medarex and Bristol-Myers Squibb are developing ipilimumab, an immunostimulatory human antibody against cytotoxic T-lymphocyte antigen-4, for the potential combination or monotherapy treatment of melanoma, prostate, breast, renal and other cancers, as well as HIV infection.Entities:
Mesh：
Substances：
Year: 2005 PMID： 16370382
Source DB: PubMed Journal: Curr Opin Mol Ther ISSN： 1464-8431